The Acuitas AMR Gene Panel helps to advance your diagnostic capabilities using multiplexed PCR to provide rapid and comprehensive resistance gene detection from a pure isolate in about 2.5 hours to aid in the management of patients.

Acuitas AMRGene logo» Acuitas AMR Gene Panel

» Acuitas Lighthouse

 

AMR infographic

The AMR Challenge

Antibiotic resistance is one of the greatest global public health challenges of our time.1

  • More than 2.8 million antibiotic-resistant infections occur in the U.S. each year, and more than 35,000 people die as a result.2
  • Culture-based AST is routine and considered the gold standard, but it requires days, can be subjective and the data may be insufficient.
  • Empiric treatment while waiting for lab result is costly and leads to more antibacterial resistance and worsening patient outcomes. 30% of antibiotic prescriptions may be inappropriate.3

Managing patients with resistant bacterial infections is challenging and costly.

  • AMR adds $20 billion to annual US healthcare costs.4
  • Patients infected with resistant bacteria have a longer median length of stay (LOS) of 5 days.5
  • The average cost of a US 3-day hospital stay is around $30,000.6

Acuitas AMR Gene Panel has the capability to rapidly detect resistance markers that are among the most serious threats on CDC’s list.

  • Carbapenem-resistant Enterobacterales “Also known as Nightmare Bacteria”
  • ESBL-producing Enterobacterales
  • Vancomycin-resistant Enterococci (VRE)
  • Multidrug-resistant Pseudomonas aeruginosa

  1. https://www.cdc.gov/antibiotic-use/community/about/antibiotic-resistance-faqs.html
  2. https://www.cdc.gov/drugresistance/biggest-threats.html
  3. https://www.cdc.gov/media/releases/2016/p0503-unnecessary-prescriptions.html
  4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6929930/
  5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2798544/
  6. https://www.healthcare.gov/why-coverage-is-important/protection-from-high-medical-costs/